EE200300179A - Humaniseeritud LT-ß-R-i vastased antikehad - Google Patents
Humaniseeritud LT-ß-R-i vastased antikehadInfo
- Publication number
- EE200300179A EE200300179A EEP200300179A EEP200300179A EE200300179A EE 200300179 A EE200300179 A EE 200300179A EE P200300179 A EEP200300179 A EE P200300179A EE P200300179 A EEP200300179 A EE P200300179A EE 200300179 A EE200300179 A EE 200300179A
- Authority
- EE
- Estonia
- Prior art keywords
- antibodies
- humanized anti
- humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24028500P | 2000-10-13 | 2000-10-13 | |
US27528901P | 2001-03-13 | 2001-03-13 | |
US29998701P | 2001-06-21 | 2001-06-21 | |
PCT/US2001/032140 WO2002030986A2 (en) | 2000-10-13 | 2001-10-12 | HUMANIZED ANTI-LT-β-R ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200300179A true EE200300179A (et) | 2003-08-15 |
Family
ID=27399340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200300179A EE200300179A (et) | 2000-10-13 | 2001-10-12 | Humaniseeritud LT-ß-R-i vastased antikehad |
Country Status (25)
Country | Link |
---|---|
US (2) | US7429644B2 (is) |
EP (1) | EP1326897A2 (is) |
JP (1) | JP2004532608A (is) |
KR (1) | KR20030041164A (is) |
CN (1) | CN1547590A (is) |
AR (1) | AR035352A1 (is) |
AU (2) | AU2002211747B2 (is) |
BG (1) | BG107802A (is) |
BR (1) | BR0114646A (is) |
CA (1) | CA2425809A1 (is) |
CZ (1) | CZ20031307A3 (is) |
EA (1) | EA006945B1 (is) |
EE (1) | EE200300179A (is) |
GE (1) | GEP20063752B (is) |
HU (1) | HUP0302573A2 (is) |
IL (1) | IL155340A0 (is) |
IS (1) | IS6779A (is) |
MX (1) | MXPA03003144A (is) |
NO (1) | NO20031642L (is) |
NZ (1) | NZ525793A (is) |
PL (1) | PL366307A1 (is) |
SK (1) | SK5672003A3 (is) |
TR (2) | TR200300478T2 (is) |
WO (1) | WO2002030986A2 (is) |
YU (1) | YU28503A (is) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
EP1539793A4 (en) * | 2002-07-01 | 2006-02-01 | HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA | |
EP1583503A4 (en) * | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF |
MXPA05006663A (es) * | 2002-12-20 | 2005-09-30 | Biogen Idec Inc | Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos. |
EP1641827A2 (en) | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
SG151294A1 (en) * | 2004-03-23 | 2009-04-30 | Biogen Idec Inc | Receptor coupling agents and therapeutic uses thereof |
US8153123B2 (en) * | 2004-12-09 | 2012-04-10 | La Jolla Institute For Allergy And Immunology | Method for restoring dendritic cell populations |
WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
EP2500030B2 (en) | 2005-11-04 | 2018-08-08 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
JP2007295524A (ja) * | 2006-03-28 | 2007-11-08 | Denso Corp | 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム |
ES2514495T3 (es) * | 2006-05-25 | 2014-10-28 | Glaxo Group Limited | Anticuerpos humanizados modificados anti-interleucina-18 |
US20120282245A1 (en) | 2006-10-03 | 2012-11-08 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
NZ576032A (en) | 2006-10-12 | 2012-03-30 | Genentech Inc | Antibodies to lymphotoxin-alpha |
CA2666934A1 (en) * | 2006-10-20 | 2008-04-24 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
BRPI0716299A2 (pt) | 2006-11-02 | 2013-08-13 | Genentech Inc | anticorpos murino,anticorpo quimÉrico, domÍnios variÁveis de um anticorpo humanizado, anticorpos anti-fator d humanizado, polipeptÍdeos, anticorpo humanizado, fragmento de anticorpo, Ácidos nuclÉico isolados, vetores , linhagem celular, composiÇço, uso, mÉtodo para produÇço de um anticorpo anti-fator d humanizado ou fragmentos destes e anticorpos |
US8003761B2 (en) * | 2007-01-23 | 2011-08-23 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
BRPI0813645A2 (pt) | 2007-06-25 | 2014-12-30 | Esbatech Alcon Biomed Res Unit | Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
CR20160132A (es) | 2013-08-12 | 2016-08-25 | Genentech Inc | Composiciones y método para tratar condiciones asociadas con el complemento |
WO2015168468A1 (en) | 2014-05-01 | 2015-11-05 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
AR102521A1 (es) | 2014-11-06 | 2017-03-08 | Hoffmann La Roche | Variantes de región fc con unión de fcrn modificada y métodos de utilización |
CR20180097A (es) * | 2015-07-14 | 2018-05-25 | Immunext Inc | Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana |
JP2018536650A (ja) | 2015-10-30 | 2018-12-13 | ジェネンテック, インコーポレイテッド | 抗d因子抗体変異体コンジュゲート及びその使用 |
CN108289951A (zh) | 2015-10-30 | 2018-07-17 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体和缀合物 |
CN109476756B (zh) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | 一种多特异性Fab融合蛋白及其用途 |
AU2020401755A1 (en) | 2019-12-11 | 2022-08-04 | Cilag Gmbh International | Multispecific binding molecules comprising LTBR and EDB binding domains and uses thereof |
WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
MX2024007314A (es) | 2021-12-20 | 2024-06-26 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden. |
WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2023218320A1 (en) * | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ATE201879T1 (de) | 1990-06-27 | 2001-06-15 | Biogen Inc | Oberflächenkomplexbildung von lymphotoxin |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE69334224D1 (de) | 1992-12-04 | 2008-07-17 | Biogen Idec Inc | Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon |
PL185364B1 (pl) * | 1995-01-26 | 2003-04-30 | Biogen | Kompozycje farmaceutyczne do leczenia albo zmniejszenia zaawansowania, ciężkości albo skutków powstawania nowotworu |
US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US7060667B1 (en) | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
PT1051187E (pt) | 1998-01-30 | 2004-03-31 | Biogen Inc | Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt) |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
EP1539793A4 (en) | 2002-07-01 | 2006-02-01 | HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA | |
MXPA05006663A (es) | 2002-12-20 | 2005-09-30 | Biogen Idec Inc | Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos. |
EP1583503A4 (en) | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF |
-
2001
- 2001-10-12 KR KR10-2003-7005232A patent/KR20030041164A/ko not_active Application Discontinuation
- 2001-10-12 EA EA200300464A patent/EA006945B1/ru not_active IP Right Cessation
- 2001-10-12 EE EEP200300179A patent/EE200300179A/xx unknown
- 2001-10-12 BR BRPI0114646-7A patent/BR0114646A/pt not_active IP Right Cessation
- 2001-10-12 GE GE5165A patent/GEP20063752B/en unknown
- 2001-10-12 SK SK567-2003A patent/SK5672003A3/sk not_active Application Discontinuation
- 2001-10-12 TR TR2003/00478T patent/TR200300478T2/xx unknown
- 2001-10-12 CZ CZ20031307A patent/CZ20031307A3/cs unknown
- 2001-10-12 TR TR2006/02095T patent/TR200602095T2/xx unknown
- 2001-10-12 AU AU2002211747A patent/AU2002211747B2/en not_active Expired - Fee Related
- 2001-10-12 YU YU28503A patent/YU28503A/sh unknown
- 2001-10-12 WO PCT/US2001/032140 patent/WO2002030986A2/en active Application Filing
- 2001-10-12 JP JP2002534371A patent/JP2004532608A/ja not_active Withdrawn
- 2001-10-12 CN CNA018205917A patent/CN1547590A/zh active Pending
- 2001-10-12 EP EP01979824A patent/EP1326897A2/en not_active Withdrawn
- 2001-10-12 NZ NZ525793A patent/NZ525793A/en unknown
- 2001-10-12 PL PL01366307A patent/PL366307A1/xx not_active Application Discontinuation
- 2001-10-12 HU HU0302573A patent/HUP0302573A2/hu unknown
- 2001-10-12 IL IL15534001A patent/IL155340A0/xx unknown
- 2001-10-12 MX MXPA03003144A patent/MXPA03003144A/es not_active Application Discontinuation
- 2001-10-12 AR ARP010104807A patent/AR035352A1/es not_active Application Discontinuation
- 2001-10-12 AU AU1174702A patent/AU1174702A/xx active Pending
- 2001-10-12 CA CA002425809A patent/CA2425809A1/en not_active Abandoned
-
2003
- 2003-04-10 US US10/412,406 patent/US7429644B2/en not_active Expired - Fee Related
- 2003-04-10 NO NO20031642A patent/NO20031642L/no not_active Application Discontinuation
- 2003-04-11 IS IS6779A patent/IS6779A/is unknown
- 2003-05-12 BG BG107802A patent/BG107802A/bg unknown
-
2008
- 2008-06-30 US US12/165,276 patent/US20090092601A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TR200300478T2 (tr) | 2004-10-21 |
US20090092601A1 (en) | 2009-04-09 |
WO2002030986A2 (en) | 2002-04-18 |
WO2002030986A3 (en) | 2003-03-13 |
MXPA03003144A (es) | 2004-12-06 |
PL366307A1 (en) | 2005-01-24 |
SK5672003A3 (en) | 2003-10-07 |
AU2002211747B2 (en) | 2007-11-29 |
EA200300464A1 (ru) | 2003-10-30 |
HUP0302573A2 (hu) | 2003-10-28 |
BR0114646A (pt) | 2006-02-21 |
JP2004532608A (ja) | 2004-10-28 |
NZ525793A (en) | 2008-04-30 |
YU28503A (sh) | 2006-05-25 |
EP1326897A2 (en) | 2003-07-16 |
EA006945B1 (ru) | 2006-06-30 |
CA2425809A1 (en) | 2002-04-18 |
US7429644B2 (en) | 2008-09-30 |
CN1547590A (zh) | 2004-11-17 |
NO20031642L (no) | 2003-06-13 |
AU1174702A (en) | 2002-04-22 |
BG107802A (bg) | 2004-01-30 |
AR035352A1 (es) | 2004-05-12 |
IL155340A0 (en) | 2003-11-23 |
CZ20031307A3 (cs) | 2003-10-15 |
GEP20063752B (en) | 2006-02-27 |
NO20031642D0 (no) | 2003-04-10 |
US20040058394A1 (en) | 2004-03-25 |
IS6779A (is) | 2003-04-11 |
TR200602095T2 (tr) | 2007-02-21 |
KR20030041164A (ko) | 2003-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200300179A (et) | Humaniseeritud LT-ß-R-i vastased antikehad | |
DE60222658D1 (de) | Monoklonaler anti-cd-40-antikörper | |
IL156030A0 (en) | Humanized antibodies | |
IS6982A (is) | Mótefni gegn VLA-1 | |
DK1501856T3 (da) | Anti-HER2 antistofvarianter | |
NO20044347L (no) | Anti-alfavbeta6-antistoff | |
IL166244A0 (en) | Super humanized antibodies | |
IS2940B (is) | Mótefni gegn CD40 | |
DE50100900D1 (de) | Fixierelement | |
DK1314437T3 (da) | Stabiliserede antistofindeholdende præparater | |
DE10085449T1 (de) | Fixiervorrichtung | |
EE200300569A (et) | CD44v6-spetsiifilised antikehad | |
DK1164375T3 (da) | Assay til antitransglutaminaseantistoffer | |
FI20011055A0 (fi) | Heveiiniä sitovat monoklonaaliset vasta-aineet | |
NO20011006D0 (no) | Høy-affinitets antistoffer | |
FI20020807A0 (fi) | Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita | |
ITPD20000192A0 (it) | Anticorpi policlonali | |
DE60135621D1 (de) | Fixiergerät | |
AR028262A1 (es) | Anticuerpos especificos de fap-alfa humanos | |
DK1503799T3 (da) | Immunogent, monoklonalt antistof | |
GB0030139D0 (en) | Monoclonal antibody | |
GB0029846D0 (en) | Monoclonal antibody | |
GB0003359D0 (en) | Monoclonal antibodies | |
GB0008160D0 (en) | Monoclonal antibodies | |
DE60239895D1 (de) | Humanisierte super-antikörper |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC1A | Change of owner name |